Introduction
Most small protein therapeutics, including not only many of the alternative recombinant antibody formats (Kontermann, 2010) but also the emerging class of alternative scaffold proteins (Nuttall and Walsh, 2008; Gebauer and Skerra, 2009 ), suffer from a short serum half-life mainly due to rapid renal clearance (Batra et al., 2002) . Consequently, treatment requires frequent applications or infusions in order to maintain an effective concentration over a prolonged period of time. Strategies to extend the plasma half-life of therapeutic proteins have, therefore, attracted increasing interest (Kontermann, 2009 (Kontermann, , 2011 Pisal et al., 2010) .
Several half-life extension strategies have been developed in recent years (Kontermann, 2009 (Kontermann, , 2011 , including strategies such as PEGylation and hyperglycosylation with the aim to increase the hydrodynamic volume of the protein and thus to reduce renal clearance, as well as strategies utilizing recycling processes executed by the neonatal Fc receptor (FcRn), which is responsible for the extraordinary long halflives of serum IgGs and of serum albumin (Kim et al., 2006) . For example, albumin has been employed for half-life extension through the generation of albumin fusion proteins. Several albumin fusion proteins, e.g. albinterferon alfa-2b and a coagulation factor IX-HSA fusion protein, have already entered clinical trials (Metzner et al., 2009; Flisiak and Flisiak, 2010) . In addition, various molecules exhibiting albumin-binding activity have been used for half-life extension. For this approach, the albumin-binding moiety is coupled or fused to the therapeutic protein leading to reversible binding to serum albumin after administration. Such albumin-binding molecules include fatty acids, organic molecules, peptides, single-chain Fv, domain antibodies, nanobodies but also domains from naturally occurring proteins capable of binding albumin (for review see: Kontermann, 2009 ). For example, an albumin-binding domain (ABD) from streptococcal protein G was used to prolong the plasma halflife of recombinant antibodies and Affibody molecules Andersen et al., 2011) . Fusion of the ABD resulted in similar half-lives as seen for an albumin fusion protein and an improved tumor accumulation as shown for a bispecific single-chain diabody (scDbCEACD3) directed against carcinoembryonic antigen (CEA) and CD3 (Stork et al., , 2009 ). These studies, however, also revealed that albumin and ABD fusion proteins do not reach the long half-life of IgG molecules. Attempts to further prolong half-life by applying an ABD with increased affinity for albumin resulted only in a marginal improvement (Hopp et al., 2010) .
Non-covalent interaction with serum IgG might represent a feasible alternative to binding to serum albumin. This approach was already tested with a bispecific diabody (Db aHEL-aGMA) with affinity for mouse Fcg1, which prolonged the terminal plasma half-life of the diabody from 1.7 to 10 h in mice (Holliger et al., 1997) . Immunoglobulin-binding domains (IgBD) are known from various bacterial proteins, e.g. staphylococcal protein A (SpA) (Tashiro and Montelione, 1995; Sidorin and Solov'eva, 2011) . These IgBDs have a length of 50 -60 amino acid residues and form either a three-a-helix bundle or a compact structure composed of a four-stranded b-sheet and one-a-helix (Tashiro and Montelione, 1995) . The primary binding site on IgG is located at the C H 2-C H 3 interface of the heavy chain (Deisenhofer, 1981; Sauer-Eriksson et al., 1995) . However, most of the bacterial IgBDs from proteins A, G and L are also capable of binding to different regions of the Fab fragment (Tashiro and Montelione, 1995) . Recently, it was shown that a large IgG-toxin immunoconjugate generated by in vitro complexation of a chimeric antiepidermal growth factor receptor IgG with a fusion protein composed of Pseudomonas exotoxin and two copies of the Z domain, a modified version of the IgBD B of SpA, exhibits an extended half-life in mice (Mazor et al., 2007) .
Here, we used the domain B of SpA to investigate its effect on the half-life of a single-chain diabody (scDbCEACD3). The SpA B was fused to the C-terminus of the scDb and the resulting fusion protein scDb-SpA B was produced in HEK293 cells. The fusion protein retained full antigen-binding activity and was capable to simultaneously bind to IgG. This resulted in a strongly prolonged serum half-life as compared with the unmodified scDb, although it did not reach the half-life seen for IgG, which might be due to competition for binding by the FcRn (Raghavan et al., 1994) . Nevertheless, our study clearly demonstrates that bacterial IgBDs can be employed to extend the serum half-life of small recombinant proteins.
Materials and methods

Materials
Horseradish peroxidase-conjugated anti-His-tag antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and fluorescein isothiocyanate (FITC)-conjugated mouse anti-His-tag antibody from Dianova (Hamburg, Germany). CEA was obtained from Europa Bioproducts (Cambridge, UK). Human and mouse serum IgG was purchased from Sigma. The human colon adenocarcinoma cell line LS174T was purchased from ECACC (Wiltshire, UK) and cultured in RPMI, 5% fetal bovine serum (FBS), 2 mM glutamine (Invitrogen, Karlsruhe, Germany). Jurkat cells were cultured in RPMI, 10% FBS, 2 mM glutamine. Buffy coats from healthy human donors were obtained from the blood bank (Ulm, Germany). The DuoSet IL-2 ELISA Development System kit was purchased from R&D Systems (Nordenstadt, Germany). CD1 mice were purchased from Elevage Janvier (Le Genest St Isle, France).
Construction and production of an scDb-SpA B fusion protein DNA encoding the SpA B domain was synthesized by GeneArt (Regensburg, Germany) adding a NotI and XbaI restriction site at the 5 0 and 3 0 end, respectively, for cloning into mammalian expression vector pSecTagAHis scDbCEACD3. HEK293 cells were stably transfected and scDb-SpA B was purified from cell culture supernatant by immobilized metal-ion-affinity chromatography (IMAC) essentially as described previously .
Enzyme-linked immunosorbent assay
CEA (300 ng/well) or IgG (500 ng/well) was coated overnight at 48C and remaining binding sites were blocked with 2% (w/v) dry milk/phosphate-buffered saline (PBS). Purified recombinant antibodies and serum samples were titrated in duplicates and incubated for 1 h at RT. For determination of pH dependence of binding, all incubation and washing steps were performed with PBS adjusted to the indicated pH. Detection was performed with mouse HRP-conjugated anti-His-tag antibody using 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) substrate (0.1 mg/ml TMB, 100 mM sodium acetate buffer pH 6.0, 0.006% H 2 O 2 ). The reaction was stopped with 50 ml of 1 M H 2 SO 4 . Absorbance was measured at 450 nm in an enzyme-linked immunosorbent assay (ELISA)-reader.
Flow cytometry
Binding to CEA-and CD3-expressing cells was determined by flow cytometry (Benedict et al., 1997) . LS174T or Jurkat cells (2.5 Â 10 5 ) were incubated with dilution series of antibodies for 2 h at 48C. Cells were then washed with PBS, 2% FBS, 0.02% NaN 3 (PBA) and bound antibodies were detected with FITC-conjugated mouse anti-His-tag antibody. Data were fitted with GraphPrism software (La Jolla, CA, USA) from three independent binding curves. From these three individual EC 50 the mean and standard deviation was calculated.
Size exclusion chromatography
Apparent molecular weights and formation of scDb-SpA B IgG complexes were analyzed by high-performance liquid chromatography size exclusion chromatography (SEC) using a BioSuite 250 (Waters Corporation, Milford, MA, USA) and a flow rate of 0.5 ml/min. The following standard proteins were used: thyroglobulin, b-amylase, bovine serum albumin, carbonic anhydrase, cytochrome c. Complex formation of scDb-SpA B with human IgG was analyzed by incubating equimolar amounts of scDb-SpA B and IgG (1.5 mM) in PBS at room temperature for 1 h and subsequent analysis by size exclusion chromatography.
Interleukin-2 release assay
Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated from buffy coat as described before . 1 Â 10 5 LS174T cells/100 ml/well were seeded in 96-well plates. The next day supernatant was removed and 150 ml of recombinant antibody was added. After 1 h pre-incubation at 378C, 2 Â 10 5 PBMC/50 ml/well was added. PBMCs had been thawed the day before and seeded on a culture dish. Only cells that remained in suspension were used for the assay. After addition of PBMCs, the 96-well plate was incubated for 24 h at 378C, 5% CO 2 .
Plates were centrifuged and cell-free supernatant was collected. Concentration of human interleukin (IL)-2 in the supernatant was determined using the DuoSet IL-2 ELISA kit (R&D Systems) following the manufacturer's protocol.
Affinity measurements
Affinities of scDb-SpA B for human and mouse serum IgG at different pH were determined by quartz crystal microbalance measurements (Attana A-100 C-Fast system). Serum IgG was chemically immobilized on an low nonspecific-binding carboxyl sensor chip according to the manufacturer's protocol at a density resulting in a signal increase of 65 -95 Hz. Binding experiments were performed in PBST (0.1% Tween 20) pH 7.4 or pH 6.0 with at a flow rate of 25 ml/min. The chip was regenerated with 25 ml 10 mM glycine-HCl pH 3.0.
Before each measurement, a baseline was measured which was subtracted from the binding curve. Data were collected by Attester 3.0 (Version 3.1.1.8, Attana, Stockholm, Sweden) and analyzed by Attache Office Evaluation Software (Version 3.3.4), using a mass transport model for curve fitting.
Pharmacokinetics
Animal care and all experiments performed were in accordance with federal guidelines and have been approved by university and state authorities. CD1 mice (8 -16 weeks, weight between 30 and 40 g) received an intravenous (i.v.) injection of 25 mg scDb-SpA B in a total volume of 150 ml. In time intervals of 3 min, 30 min, 1 h, 2 h, 6 h, 1 day and 3 days blood samples (50 ml) were taken from the tail and incubated on ice. Clotted blood was centrifuged at 13 000 g for 10 min, 48C and serum samples were stored at 2208C. Serum concentrations of CEA-binding recombinant antibodies were determined by ELISA (as described above). For comparison, the first value (3 min) was set to 100%. Half-lives (t 1/2 a, t 1/2 b) and area-under-the-curve (AUC) were calculated with Excel. For statistics, Student's t-test was applied.
Results
Molecular characterization of an scDb-SpA B fusion protein ScDbCEACD3-SpA B ( Fig. 1 ) was purified from cell culture supernatant of stably transfected HEK293 cells by IMAC. A yield of 8.2 mg/l supernatant was obtained. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS -PAGE) analysis revealed a single band under reducing and nonreducing conditions (Fig. 1d) . Compared with unmodified scDb, the apparent molecular mass was increased by 7 -60 kDa under reducing conditions. ScDb-SpA B retained its binding activity for CEA as shown by ELISA (Fig. 2) . In the presence of human IgG (650 nM), binding was reduced at lower scDb-SpA B concentrations but was increased at 300 nM of scDb-SpA B . ScDb-SpA B also showed binding to CEA-expressing LS174T cells and CD3-expressing Jurkat cells in flow cytometry (Fig. 3) . EC 50 values were 1.0 + 0.5 and 0.9 + 0.2 nM for binding to LS174T and Jurkat, respectively. No binding was observed with HEK293 included as negative control (not shown). In the absence of human serum IgG, binding of scDb-SpA B was similar to that observed for scDb. In the presence of human serum IgG (65 or 650 nM), binding was not or only marginally affected at low concentrations of scDb-SpA B . A strongly increased binding was seen at higher scDb-SpA B concentrations reaching a maximum at a concentration around that of the added IgG (Fig. 3a -d) . Human IgG had no effect on cell binding of the unmodified scDb ( Fig. 3e and f ) . Binding of the human IgG to cell-bound scDb-SpA B was demonstrated with an antihuman Fab antibody for detection ( Fig. 3g and h) , also indicating that scDb-SpA B is capable of binding simultaneously to the antigen and IgG.
Interaction of scDb-SpA B with IgG
Binding of scDb-SpA B to IgG was further shown by ELISA with immobilized immunoglobulins (Fig. 4) . Strong binding was observed using human serum IgG (huIgG) or a humanized IgG1 . Binding was also seen with mouse serum IgG (moIgG) or a mouse monoclonal IgG2a antibody (H398), although binding was 10-to 100-fold weaker than that seen for the human IgGs (Fig. 4a) . For all tested immunoglobulins, binding was reduced at pH 6.0 as compared with binding at pH 7.4 (Fig. 4b) . A comparison of binding at different pH values and a constant scDb-SpA B concentration (15 nM scDb-SpA B for human IgG and 150 nM for mouse IgG) showed that binding was pH dependent. At pH 4.0, binding was almost completely abolished (Fig. 4c) . Affinities for human and mouse serum IgG were further determined by quartz crystal microbalance (QCM) measurements. An affinity of 8.5 Â 10 29 M was determined for human serum IgG at pH 7.4, while that for mouse serum IgG was 3.8 Â 10 27 M (Fig. 5, Table 1 ). At pH 6, affinities were reduced to 3.5 Â 10 27 M for human serum IgG and to 1.5 Â 10 25 M for mouse serum IgG, respectively (Fig. 5) . These numbers represent most likely average values because of the heterogeneity Fig. 2 . Binding of scDb-SpA B to CEA in ELISA. Binding of scDb-SpA B to immobilized CEA was determined in the presence or absence of human serum IgG (100 mg/ml). Half-life extension of a scDb by fusion to SpA B of the IgG preparations composed of different IgG subclasses as well as the different binding sites of SpA B on the Fc and Fab fragments of IgG (Jansson et al., 1998) . IgG binding was further analyzed by SEC (Fig. 6) . Both scDb-SpA B and human IgG1 migrated in SEC at single peaks. After mixing equimolar amounts of scDb-SpA B and human IgG1, the peak for scDb-SpA B had completely vanished, the peak for IgG1 was strongly decreased and an additional peak of a higher molecular mass appeared indicating that scDb-SpA B had bound to IgG1 in a one-to-one or one-to-two stoichiometry.
Effector cell retargeting by scDb-SpA B
The scDb-SpA B fusion protein was analyzed in vitro for its ability to retarget T-cells to target cells and to induce IL-2 release from the effector cells (Fig. 7) . Compared with the unmodified scDb, the scDb-SpA B fusion protein showed a strongly increased IL-2 release in the absence of human IgG. In the presence of human IgG, the activity of scDb-SpA B was greatly reduced, while human IgG had no effect on scDb-mediated IL-2 release. Nevertheless, this experiment Fig. 3 . Binding of scDb-SpA B to cells. Binding of scDb-SpA B to CD3-positive Jurkat cells and CEA-expressing LS174T cells was analyzed in the absence or presence of human IgG using either 10 mg/ml IgG (a, b) or 100 mg/ml IgG (c, d), respectively. As a control, binding of the wild-type scDb was also analyzed in the absence or presence of 100 mg/ml human IgG (e, f ). Binding was detected with an FITC-labeled anti-His-tag antibody. In a further experiment, we compared detection of bound scDb-SpA B using an FITC-labeled anti-His-tag antibody or an FITC-labeled anti-human Fab antibody (g, h).
indicates that the scDb-SpA B fusion protein is capable of binding to the two antigens and IgG simultaneously. In the absence of target cells, a marginal induction of IL-2 release was observed for scDb-SpA B and scDb. For scDb-SpA B , IL-2 secretion was almost completely abolished in the presence of excess amounts of IgG, while no effects were observed for scDb.
Pharmacokinetics
Half-life of scDb-SpA B was analyzed after a single i.v. injection into CD1 mice. Serum concentrations were determined by ELISA, i.e. detecting molecules with CEA-binding activity. Compared with scDb, the scDb-SpA B fusion protein showed a strongly prolonged circulation in the blood (Fig. 8) . A terminal half-life of 11.8 h was determined for scDb-SpA B (Table 2) .
Discussion
Serum albumin and IgGs exhibit extraordinary long plasma half-lives compared with all the other plasma proteins (Kontermann, 2009 ). Besides possessing a molecular mass above the renal cut-off, the long half-life is determined by FcRn-mediated recycling, which is especially prominent for IgGs. Thus, in a comparative study of half-lives of albumin and IgG in wild type and b2-microglobulin (b2m) knockout mice, the half-life of albumin was reduced from 35 to 25 h, while that of IgG was reduced from 95 to 19 h (Chaudhury et al., 2003) . While fusion, conjugation and binding of protein therapeutics to serum albumin have become established methods to extend the half-life of these proteins (Chuang et al., 2002) , little work has been performed employing serum immunoglobulins. Currently, the use of immunoglobulins for half-life extension purposes is limited to fusion of a therapeutic protein to an Fc region resulting in homodimeric molecules with increased size and divalent presentation of the therapeutic moiety (Huang, 2009) . Here, we show that fusion of a single IgBD from staphyloccocal protein A to a recombinant bispecific antibody results in a drastically prolonged half-life.
The bispecific scDb-SpA B fusion protein was capable of binding to its two antigens as well as IgG as shown by ELISA and flow cytometry. In the absence of IgG, antigen binding was similar to that of the unmodified scDb. In an earlier study, it was also shown that fusion of SpA B to an anti-digoxin scFv does not impair binding to the antigen and that the fusion protein is capable of binding to IgG in ELISA (Tai et al., 1990) . Interestingly, in the presence of IgG, binding was somewhat decreased at lower scDb-SpA B concentrations and increased at higher concentrations. This finding indicates that IgG, possessing two binding sites for IgBDs in the Fc region and additionally two low-affinity-binding sites in the Fab arm (Jansson et al., 1998) , forms complexes, which can result in improved binding, probably due to avidity effects. Binding of IgG to cell-bound scDb-SpA B was confirmed with an anti-human Fab antibody for detection. As shown by SEC analysis, incubation of scDb-SpA B and human IgG at equimolar concentrations results in complete disappearance of free scDb-SpA B while still some free IgG is detectable. This finding indicates that there is a preferred formation of complexes composed of one IgG and two scDb-SpA B molecules. However, further studies are necessary in order to determine the exact stoichiometry of the scDb-SpA B -IgG complexes.
Incubation of immobilized target cells and PBMCs with the anti-CEA Â anti-CD3 scDb-SpA B fusion protein resulted in an increased IL-2 release as compared with scDb. This finding indicates that the SpA B domain induces activation of PBMCs. Recently, it was found that SpA but also single SpA-IgBDs are capable of binding to TNFR1 and activation of receptor signaling through NF-kB (Gómez et al., 2006; Kumar et al., 2007; Claßen et al., 2011) . Activation of TNFR1 might therefore lead to a costimulation of T-cell receptor-mediated IL-2 expression and secretion (Evangelidou et al., 2010) . In our experiments, IL-2 release mediated by scDb-SpA B was strongly reduced in the Fig. 4 . Binding of scDb-SpA B to IgG. Binding of scDb-SpA B to human or mouse IgG was analyzed by ELISA with immobilized human serum IgG (huIgG), the monoclonal humanized antibody humex (human IgG1) , mouse serum IgG (moIgG), and mouse monoclonal antibody H398 (mouse IgG2a). Binding was analyzed at pH 7.4 (a) or pH 6.0 (b). (c) Titration of binding of scDb-SpA B to huIgG or moIgG at different pH using the indicated concentrations of scDb-SpA B .
Half-life extension of a scDb by fusion to SpA B presence of IgG indicating that stimulation of effector cells is blocked by binding to IgG. This is in accordance with the finding that the protein A binding site for TNFR1 is overlapping with the IgG-Fc binding site (Gómez et al., 2006) .
A 10-to 100-fold stronger binding of scDb-SpA B to human IgG as compared with mouse IgG was determined in our study. This is in accordance with previous findings, e.g. obtained for an SpA B -scFv fusion protein with the SpA B fused to the N-terminus of an scFv (Tai et al., 1990) . As expected, binding of IgG to scDb-SpA B was pH-dependent and strongly declined at pH values ,6 (Gore et al., 1992) . Lowering the pH from 7.4 to 6.0 resulted in an 45-fold reduced affinity of scDb-SpA B for human serum IgG and a 43-fold reduced affinity for mouse serum IgG. A pH-dependent binding may have a direct influence on FcRn-mediated recycling, which requires that the SpA B fusion protein stays bound to IgG-FcRn complexes in the acidic environment of the early endosome ( pH 6.3 -6.8) and tubular recycling endosomes ( pH 6.5) (Jovic et al., 2010) . Furthermore, efficient FcRn-mediated recycling requires that the SpA B domain does not interfere with binding of IgG to the FcRn. Although the SpA B domain is capable of binding to the V H domain derived from certain germline genes, the major binding site of SpA B is located at the C H 2-C H 3 domain interface of the Fc region, which is overlapping with the binding site for FcRn (Deisenhofer, 1981; Burmeister et al., 1994; Kim et al., 1994) . Inhibition of binding of rat FcRn to human IgG was described for domain Z, a genetically engineered functional analog of SpA B (Raghavan et al., 1994) . We observed an increased half-life of 11.8 h for the scDb-SpA B fusion protein compared with 1.3 h for the unmodified scDb, translating in a 25-fold increased AUC. Because the molecular mass of the scDb-SpA B is only increased by 7 kDa through fusion of the scDb-SpA B , we exclude that half-life extension was due to an increased hydrodynamic radius of the fusion protein.
Indeed, a Stokes radius of 2.6 nm was determined for scDb-SpA B by SEC, which is identical to that of the unmodified scDb. Our in vitro binding data support the assumption that the scDb-SpA B fusion protein binds to serum immunoglobulins after i.v. injection. Compared with the scDb-SpA B fusion protein, these complexes composed of one immunoglobulin and one or several bound scDb-SpA B fusion protein exhibit a strongly increased hydrodynamic radius. The contribution of the increased hydrodynamic radius and a recycling by the FcRn to the extended half-life is currently not known and could be analyzed in further studies, for example, using FcRn knockout mice (Chaudhury et al., 2003) . Furthermore, half-life might be influenced by the formation of immune complexes leading to rapid clearance from circulation by complement or Fc receptors (Rehlaender and Cho, 1998 ). We did not observe higher-order complexes by SEC analysis, Recently, an extended serum half-life was also shown for a fusion protein (ZZ-PE38) comprising two Z domains and a Pseudomonas exotoxin A (ETA) fragment (Mazor et al., 2007) . This fusion protein was used to produce a large IgG-toxin immunoconjugate by complexation with a chimeric anti-HER2 monoclonal antibody in vitro. After i.v. injection into mice, the half-life was extended to 4 h for the antibody-ZZ-PE38 complex compared with 18 min for an scFv-ETA molecule. Although using two IgBDs in tandem and preformation of IgG complexes in vitro, this study supports the finding that IgBDs from protein A can be applied to extend the half-life of small recombinant protein therapeutics.
The measured half-life of scDb-SpA B is similar to that of mouse IgG in FcRn knockout mice (Chaudhury et al., 2003) , indicating that FcRn recycling is strongly impaired if not entirely abolished for the scDb-SpA B fusion protein. Whether this is caused by a reduced binding to IgG at acidic pH or by the interference with FcRn binding (or a mixture of both effects) is currently not known and requires further studies. Nevertheless, our study shows that fusion of an IgBD represents a feasible approach for half-life extension and leaves Calculated for 0-6 h; terminal half-lives (t 1/2 b) were calculated using the last three to four serum concentrations shown in Fig. 8 . 
